Comparison of survival outcomes and effects of therapy between subtypes of high-grade endometrial cancer – a population-based study

References

• Faber MT, Frederiksen K, Jensen A, et al. Time trends in the incidence of hysterectomy-corrected overall, type 1 and type 2 endometrial cancer in Denmark 1978–2014. Gynecol Oncol. 2017;146(2):359–367.
   PubMed Web of Science ®Google Scholar
• Kim H-J, Kim T-J, Lee Y-Y, et al. A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system. J Gynecol Oncol. 2013;24(2):120–127.
   PubMed Web of Science ®Google Scholar
• Moore K, Brewer MA. Endometrial cancer: is this a new disease? Am Soc Clin Oncol Educ Book. 2017;37:435–442.
   PubMedGoogle Scholar
• Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 Pt 1):383–397.
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17.
   PubMed Web of Science ®Google Scholar
• Suarez AA, Felix AS, Cohn DE. Bokhman redux: endometrial cancer "types" in the 21st century. Gynecol Oncol. 2017;144(2):243–249.
   PubMed Web of Science ®Google Scholar
• Ayeni TA, Bakkum-Gamez JN, Mariani A, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013;129(3):478–485.
   PubMed Web of Science ®Google Scholar
• Buhtoiarova TN, Brenner CA, Singh M. Endometrial carcinoma: role of current and emerging biomarkers in resolving persistent clinical dilemmas. Am J Clin Pathol. 2016;145(1):8–21.
   PubMed Web of Science ®Google Scholar
• Reynaers EAEM, Ezendam NPM, Pijnenborg JMA. Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer. J Surg Oncol. 2015;111(6):790–794.
   PubMed Web of Science ®Google Scholar
• Voss MA, Ganesan R, Ludeman L, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol. 2012;124(1):15–20.
   PubMed Web of Science ®Google Scholar
• Alektiar KM, McKee A, Lin O, et al. Is there a difference in outcome between stage I–II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys. 2002;54(1):79–85.
   PubMed Web of Science ®Google Scholar
• McGunigal M, Liu J, Kalir T, et al. survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers: a National Cancer Database Analysis. Int J Gynecol Cancer. 2017;27(1):85–92.
   PubMed Web of Science ®Google Scholar
• Park JY, Nam J-H, Kim Y-T, et al. Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients. Virchows Arch. 2013;462(3):289–296.
   PubMed Web of Science ®Google Scholar
• Boer S. d, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295–309.
   PubMed Web of Science ®Google Scholar
• Scharl S, Papathemelis T, Kronberger K, et al. Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry. Arch Gynecol Obstet. 2018;297(5):1245–1253.
   PubMed Web of Science ®Google Scholar
• DGGG. Diagnostik und Therapie des Endometriumkarzinoms. [Internet] [cited 2020 Dec 13]. Available from: https://www.dggg.de/leitlinien-stellungnahmen/leitlinien/leitlinie/diagnostik-und-therapie-des-endometriumkarzinoms-239/.
   Google Scholar
• Kommission Uterus der Arbeitsgemeinschaft Gynäkologische Onkologie e.V. in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e.V. sowie in der Deutschen Krebsgesellschaft e. V. Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie des Endometriumkarzinoms. 2010. [Internet] [cited 2020 Apr 18]. Available from: https://www.awmf.org/uploads/tx_szleitlinien/032-034l_S2k_Endometriumkarzinom_01.pdf.
   Google Scholar
• Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–646.
   PubMed Web of Science ®Google Scholar
• Amant F, Cadron I, Fuso L, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol. 2005;98(2):274–280.
   PubMed Web of Science ®Google Scholar
• Felix AS, Stone RA, Bowser R, et al. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer. 2011;21:877–884.
   PubMed Web of Science ®Google Scholar
• Scholten AN, Smit V, Beerman H, et al. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer. 2004;100(4):764–772.
   PubMed Web of Science ®Google Scholar
• Raffone A, Travaglino A, Mascolo M, et al. TCGA molecular groups of endometrial cancer: pooled data about prognosis. Gynecol Oncol. 2019;155(2):374–383.
   PubMed Web of Science ®Google Scholar
• Mould T, Brand A, Nijman H, et al. STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer. J Clin Oncol. 2018;36(15_suppl):TPS5615–TPS5615.
   Web of Science ®Google Scholar
• Hogberg T, Signorelli M, Oliveira CF de, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer. 2010;46(13):2422–2431.
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, Nout RA, Lybeert MLM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e631-8–e638.
   PubMed Web of Science ®Google Scholar